Zofaril Co Tablet
PDF Leaflet Revision Date: 14 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate essential hypertension.
Dosage (summary)
One tablet once daily for adults; not recommended for patients with volume or salt depletion.
Onset of Action / Duration
Onset: 2 hours, Duration: 6-12 hours
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Concomitant use with sacubitril/valsartan contraindicated
- Increased risk of angioedema with racecadotril and mTOR inhibitors
- Potassium-sparing diuretics may increase hyperkalaemia risk
Contraindications
- Hypersensitivity to zofenopril or hydrochlorothiazide
- History of angioedema with ACE inhibitors
- Severe renal impairment (CrCl < 30 mL/min)
- Severe hepatic impairment
Common side effects
- Dizziness
- Cough
- Hypotension
- Hyperkalaemia
Counselling Points
- Take once daily, with or without food
- Report any signs of infection or angioedema
- Avoid potassium supplements unless advised
Serious warnings
- Risk of severe hypotension after first dose
- Angioedema may occur
- Monitor renal function closely
Important Disclaimer
The Zofaril Co Tablet professional information leaflet below is the property of Lebasi Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
